Brenus Pharma raises $12.6M Series A (France, Jul 2026)

$12.6M
€11 million Series A extension

Reach the investors backing rounds like this

Backed by Angelor, UI Investissement +6 more · verified emails and LinkedIn on Datapile

See all 8 investors →
Generated social card
Brenus Pharma social card
Headline

Brenus Pharma raises €11 million Series A extension to advance immunotherapy for hard-to-treat solid tumours - EU-Startups

About

Brenus Pharma is a Lyon-based clinical-stage biotech startup focused on preventing cancer recurrence through innovative immunotherapy solutions. The company is developing a platform that engages the immune system to target hard-to-treat solid tumors, utilizing a novel dendritic cell-engager modality to convert cold tumors into responsive ones. This funding will help advance their next drug candidate and complete their Phase I program.

Article summary

Brenus Pharma raises €11 million Series A extension to advance immunotherapy for hard-to-treat solid tumours  EU-Startups

Founder
Paul Bravetti
CEO
Investors · 8
6 hidden
AngelorLead
FUND
UI Investissement
FUND
Related rounds
Oct 07, 2026VoltR$23.8M—France
Oct 07, 2026Netsec$9.6M—France
Oct 02, 2026C-Clerc$1.3M—France
Sep 30, 2026Inbolt$11.0M—France

11,416 investors back startups in France

You just read who funded Brenus Pharma. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.

Free account: 15 investor contact unlocks a month, no card required.

About the investors in France